Elicera Therapeutics AB (ELIC) - Total Liabilities

Latest as of September 2025: Skr6.97 Million SEK ≈ $750.01K USD

Based on the latest financial reports, Elicera Therapeutics AB (ELIC) has total liabilities worth Skr6.97 Million SEK (≈ $750.01K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Elicera Therapeutics AB liquidity resilience to evaluate the company's liquid asset resilience ratio.

Elicera Therapeutics AB - Total Liabilities Trend (2014–2024)

This chart illustrates how Elicera Therapeutics AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Elicera Therapeutics AB.

Elicera Therapeutics AB Competitors by Total Liabilities

The table below lists competitors of Elicera Therapeutics AB ranked by their total liabilities.

Company	Country	Total Liabilities
Euromedis Groupe SA PA:ALEMG	France	€23.04 Million
Denali Capital Acquisition Corp. Class A Ordinary Shares NASDAQ:DECA	USA	$11.16 Million
BTC Digital Ltd. NASDAQ:BTCT	USA	$3.99 Million
Qyou Media Inc V:QYOU	Canada	CA$12.99 Million
Horizon Petroleum Ltd V:HPL	Canada	CA$7.86 Million
Brightline Interactive, Inc. NASDAQ:BTLN	USA	$1.05 Million
ASTORY Co.Ltd KQ:241840	Korea	₩10.09 Billion
TIALIS ESSENTIAL IT PLC F:U6M	Germany	€11.21 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Elicera Therapeutics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Elicera Therapeutics AB net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.35	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.23	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.19	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Elicera Therapeutics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Elicera Therapeutics AB (2014–2024)

The table below shows the annual total liabilities of Elicera Therapeutics AB from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr6.79 Million ≈ $730.97K	-50.70%
2023-12-31	Skr13.78 Million ≈ $1.48 Million	+2.00%
2022-12-31	Skr13.51 Million ≈ $1.45 Million	+440.31%
2021-12-31	Skr2.50 Million ≈ $269.05K	+6.22%
2020-12-31	Skr2.35 Million ≈ $253.30K	+58742.88%
2019-12-31	Skr4.00K ≈ $430.46	0.00%
2018-12-31	Skr4.00K ≈ $430.46	0.00%
2017-12-31	Skr4.00K ≈ $430.46	-96.79%
2016-12-31	Skr124.60K ≈ $13.41K	-66.03%
2015-12-31	Skr366.76K ≈ $39.47K	-38.55%
2014-12-31	Skr596.87K ≈ $64.23K	--

About Elicera Therapeutics AB

ST:ELIC Sweden Biotechnology

Market Cap

$14.55 Million

Skr135.17 Million SEK

Market Cap Rank

#26163 Global

#538 in Sweden

Share Price

Skr2.79

Change (1 day)

-0.71%

52-Week Range

Skr2.30 - Skr7.90

All Time High

Skr8.56